SWOG clinical trial number
C19801

A Phase II Study of 506U78 in Patients with Refractory or Relapsed T-Lineage Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Closed
Phase
Published
Abbreviated Title
Relpased/Refractory T-lineage ALL/LBL
Activated
06/15/2000
Closed
09/12/2001
Participants
NCORP, Members, Pathologists

Research committees

Leukemia
Lymphoma

Treatment

506U78

Eligibility Criteria Expand/Collapse

Histologic diagnosis of T-lineage ALL or lymphoblastic lymphoma (LBL), refractory to at least one induction treatment regimen or in first or later relapse after achieving CR; no CNS leukemia, no history of seizure disorder or > / = Grade 3 neurologic toxicity during prior treatment of ALL/LBL. No pre-existing neuropathy >/= Grade 2 at the time of registration regardless of causality; age >/= 16 years.

Publication Information Expand/Collapse

2007

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

DJ DeAngelo;D Yu;JL Johnson;SE Coutre;RM Stone;AT Stopeck;JP Gockerman;BS Mitchell;FR Appelbaum;RA Larson Blood 109(12):5136-5142

PMid: PMID17344466 | PMC number: PMC1941786

2002

A phase II study of 2-amino-9-B-D-arabinosyl-6-methoxy-9H-purine (506U78) in patients with relapsed or refractory T-lineage acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): CALGB study 19801.

DJ De Angelo;D Yu;RK Dodge;SE Coutre;BS Mitchell;RM Stone;AT Stopeck;RA Larson Blood 100(11):198a(#743)

Other Clinical Trials

SWOG Clinical Trial Number
S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
12%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase